Ebbinghaus, M.; Wittich, K.; Bancher, B.; Lebedeva, V.; Appelshoffer, A.; Femel, J.; Helm, M.S.; Kollet, J.; Hardt, O.; Pfeifer, R.
Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer. Int. J. Mol. Sci. 2024, 25, 615.
https://doi.org/10.3390/ijms25010615
AMA Style
Ebbinghaus M, Wittich K, Bancher B, Lebedeva V, Appelshoffer A, Femel J, Helm MS, Kollet J, Hardt O, Pfeifer R.
Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences. 2024; 25(1):615.
https://doi.org/10.3390/ijms25010615
Chicago/Turabian Style
Ebbinghaus, Mira, Katharina Wittich, Benjamin Bancher, Valeriia Lebedeva, Anijutta Appelshoffer, Julia Femel, Martin S. Helm, Jutta Kollet, Olaf Hardt, and Rita Pfeifer.
2024. "Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer" International Journal of Molecular Sciences 25, no. 1: 615.
https://doi.org/10.3390/ijms25010615
APA Style
Ebbinghaus, M., Wittich, K., Bancher, B., Lebedeva, V., Appelshoffer, A., Femel, J., Helm, M. S., Kollet, J., Hardt, O., & Pfeifer, R.
(2024). Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences, 25(1), 615.
https://doi.org/10.3390/ijms25010615
